Clinical Trials
5 trialsNCT01950390 2025-12-11
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT02519322 2024-04-05
Neoadjuvant and Adjuvant Checkpoint Blockade
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02158520 2020-01-21
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
Academic and Community Cancer Research United
Phase 2 Completed
NCT00387751 2017-11-22
Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00397982 2017-06-09
Mel47
National Cancer Institute (NCI)
Phase 2 Completed